Sensible Biotechnologies (YC S21) — Unlocking the next generation of mRNA medicines
The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
Sensible Biotechnologies is a Y Combinator company in the Summer 2021 batch. Its directory entry describes it as: Unlocking the next generation of mRNA medicines. The founders listed are Miroslav Gasparek (Founder), Marian Kupculak (Founder) (Y Combinator directory entry, April 3, 2023).
Get an email when Sensible Biotechnologies changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Sensible Biotechnologies?
Get the full cited report on Sensible Biotechnologies
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
Miroslav Gasparek
Founder
Marian Kupculak
Founder
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 65 companies held here in Healthcare › Therapeutics.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on Sensible Biotechnologies?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Sensible Biotechnologies: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sensible Biotechnologies covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Sensible Biotechnologies: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sensible Biotechnologies (YC S21) — Unlocking the next generation of mRNA medicines. MentionFox, 2026-10-20. https://mentionfox.com/funding/yc-sensible-biotechnologies
